Literature DB >> 29801099

Projected Cancer Incidence Rates and Burden of Incident Cancer Cases in HIV-Infected Adults in the United States Through 2030.

Meredith S Shiels1, Jessica Y Islam2, Philip S Rosenberg1, H Irene Hall3, Evin Jacobson3, Eric A Engels1.   

Abstract

Background: Persons living with HIV (PLWH) have an elevated risk for certain types of cancer. With modern antiretroviral therapy, PLWH are aging and cancer rates are changing. Objective: To project cancer incidence rates and burden (number of new cancer diagnoses) among adult PLWH in the United States through 2030. Design: Descriptive. Setting: HIV/AIDS Cancer Match Study to project cancer rates and HIV Optimization and Prevention Economics model to project HIV prevalence. Participants: HIV-infected adults. Measurements: Projected cancer rates and burden among HIV-infected adults in the United States by age during 2006 to 2030 for AIDS-defining cancer (ADC)-that is, Kaposi sarcoma, non-Hodgkin lymphoma, and cervical cancer-and certain types of non-AIDS-defining cancer (NADC). All other cancer types were combined.
Results: The proportion of adult PLWH in the United States aged 65 years or older is projected to increase from 8.5% in 2010 to 21.4% in 2030. Age-specific rates are projected to decrease through 2030 across age groups for Kaposi sarcoma, non-Hodgkin lymphoma, cervical cancer, lung cancer, Hodgkin lymphoma, and other cancer types combined, and among those aged 65 years or older for colon cancer. Prostate cancer rates are projected to increase. The estimated total cancer burden in PLWH will decrease from 8150 cases in 2010 (2730 of ADC and 5420 of NADC) to 6690 cases in 2030 (720 of ADC and 5980 of NADC). In 2030, prostate cancer (n = 1590) and lung cancer (n = 1030) are projected to be the most common cancer types. Limitation: Projections assume that current trends in cancer incidence rates, HIV transmission, and survival will continue.
Conclusion: The cancer burden among PLWH is projected to shift, with prostate and lung cancer expected to emerge as the most common types by 2030. Cancer will remain an important comorbid condition, and expanded access to HIV therapies and cancer prevention, screening, and treatment is needed. Primary Funding Source: National Cancer Institute.

Entities:  

Mesh:

Year:  2018        PMID: 29801099      PMCID: PMC6329294          DOI: 10.7326/M17-2499

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  28 in total

1.  Permutation tests for joinpoint regression with applications to cancer rates.

Authors:  H J Kim; M P Fay; E J Feuer; D N Midthune
Journal:  Stat Med       Date:  2000-02-15       Impact factor: 2.373

2.  HIV as an independent risk factor for incident lung cancer.

Authors:  Keith Sigel; Juan Wisnivesky; Kirsha Gordon; Robert Dubrow; Amy Justice; Sheldon T Brown; Joseph Goulet; Adeel A Butt; Stephen Crystal; David Rimland; Maria Rodriguez-Barradas; Cynthia Gibert; Lesley S Park; Kristina Crothers
Journal:  AIDS       Date:  2012-05-15       Impact factor: 4.177

3.  Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort.

Authors:  Mira Hleyhel; Mira Hleyhel; Anne Marie Bouvier; Aurélien Belot; Pierre Tattevin; Jérôme Pacanowski; Philippe Genet; Nathalie De Castro; Jean-Luc Berger; Caroline Dupont; Armelle Lavolé; Christian Pradier; Dominique Salmon; Anne Simon; Valérie Martinez; Jean Philippe Spano; Dominique Costagliola; Sophie Grabar
Journal:  AIDS       Date:  2014-09-10       Impact factor: 4.177

4.  Risk of Breast, Prostate, and Colorectal Cancer Diagnoses Among HIV-Infected Individuals in the United States.

Authors:  Anna E Coghill; Eric A Engels; Maria J Schymura; Parag Mahale; Meredith S Shiels
Journal:  J Natl Cancer Inst       Date:  2018-09-01       Impact factor: 13.506

5.  Effects of Reaching National Goals on HIV Incidence, by Race and Ethnicity, in the United States.

Authors:  Evin Uzun Jacobson; Katherine A Hicks; Emily L Tucker; Paul G Farnham; Stephanie L Sansom
Journal:  J Public Health Manag Pract       Date:  2018 Jul/Aug

6.  Elevated Cancer-Specific Mortality Among HIV-Infected Patients in the United States.

Authors:  Anna E Coghill; Meredith S Shiels; Gita Suneja; Eric A Engels
Journal:  J Clin Oncol       Date:  2015-06-15       Impact factor: 44.544

7.  Contribution of Anal Sex to HIV Prevalence Among Heterosexuals: A Modeling Analysis.

Authors:  Ann O'Leary; Elizabeth DiNenno; Amanda Honeycutt; Benjamin Allaire; Simon Neuwahl; Katherine Hicks; Stephanie Sansom
Journal:  AIDS Behav       Date:  2017-10

8.  Disparities in cancer treatment among patients infected with the human immunodeficiency virus.

Authors:  Gita Suneja; Chun Chieh Lin; Edgar P Simard; Xuesong Han; Eric A Engels; Ahmedin Jemal
Journal:  Cancer       Date:  2016-05-17       Impact factor: 6.860

9.  Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States.

Authors:  Hilary A Robbins; Meredith S Shiels; Ruth M Pfeiffer; Eric A Engels
Journal:  AIDS       Date:  2014-03-27       Impact factor: 4.177

10.  Cancer stage at diagnosis in patients infected with the human immunodeficiency virus and transplant recipients.

Authors:  Meredith S Shiels; Glenn Copeland; Marc T Goodman; Janna Harrell; Charles F Lynch; Karen Pawlish; Ruth M Pfeiffer; Eric A Engels
Journal:  Cancer       Date:  2015-03-04       Impact factor: 6.921

View more
  41 in total

Review 1.  HIV and cancer in the Veterans Health Administration System.

Authors:  Keith Sigel; Lesley Park; Amy Justice
Journal:  Semin Oncol       Date:  2019-10-28       Impact factor: 4.929

2.  Short-term outcomes for lung cancer resection surgery in HIV infection.

Authors:  Keith M Sigel; Kimberly Stone; Juan P Wisnivesky; Lesley S Park; Chung Yin Kong; Michael J Silverberg; Sheldon Brown; Matthew Goetz; Maria C Rodriguez-Barradas; Cynthia Gibert; Fatma Shebl; Roger Bedimo; Roxanne Wadia; Joseph King; Kristina Crothers
Journal:  AIDS       Date:  2019-07-01       Impact factor: 4.177

3.  Healthy behavioral choices and cancer screening in persons living with HIV/AIDS are different by sex and years since HIV diagnosis.

Authors:  Akemi T Wijayabahu; Zhi Zhou; Robert L Cook; Babette Brumback; Nicole Ennis; Lusine Yaghjyan
Journal:  Cancer Causes Control       Date:  2019-02-09       Impact factor: 2.506

4.  The Current State of HIV and Aging: Findings Presented at the 10th International Workshop on HIV and Aging.

Authors:  Stephanie Shiau; Alexis A Bender; Jane A O'Halloran; Erin Sundermann; Juhi Aggarwal; Keri N Althoff; Jason V Baker; Steven Deeks; Linda P Fried; Stephen Karpiak; Maile Y Karris; Thomas D Marcotte; Jean B Nachega; Joseph B Margolick; Kristine M Erlandson; David J Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2020-09-23       Impact factor: 2.205

Review 5.  Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer.

Authors:  Kathryn Lurain; Ramya Ramaswami; Robert Yarchoan; Thomas S Uldrick
Journal:  Curr HIV/AIDS Rep       Date:  2020-10       Impact factor: 5.071

Review 6.  HIV and Aging: Reconsidering the Approach to Management of Comorbidities.

Authors:  Kristine M Erlandson; Maile Y Karris
Journal:  Infect Dis Clin North Am       Date:  2019-09       Impact factor: 5.982

7.  Advanced stage at diagnosis and elevated mortality among US patients with cancer infected with HIV in the National Cancer Data Base.

Authors:  Anna E Coghill; Xuesong Han; Gita Suneja; Chun Chieh Lin; Ahmedin Jemal; Meredith S Shiels
Journal:  Cancer       Date:  2019-05-03       Impact factor: 6.860

Review 8.  Cancer immunotherapy of patients with HIV infection.

Authors:  M Gonzalez-Cao; J Martinez-Picado; N Karachaliou; R Rosell; A Meyerhans
Journal:  Clin Transl Oncol       Date:  2018-11-17       Impact factor: 3.405

9.  Associations of Viral Seroreactivity with AIDS-Related Non-Hodgkin Lymphoma.

Authors:  Minkyo Song; Bryan A Bassig; Noemi Bender; James J Goedert; Cheryl A Winkler; Nicole Brenner; Tim Waterboer; Charles S Rabkin
Journal:  AIDS Res Hum Retroviruses       Date:  2020-03-02       Impact factor: 2.205

10.  A comparison of complete pathologic response rates following neoadjuvant chemotherapy among South African breast cancer patients with and without concurrent HIV infection.

Authors:  Sarah Nietz; Daniel S O'Neil; Oluwatosin Ayeni; Wenlong Carl Chen; Maureen Joffe; Judith S Jacobson; Alfred I Neugut; Paul Ruff; Witness Mapanga; Ines Buccimazza; Urishka Singh; Sharon Čačala; Laura Stopforth; Boitumelo Phakathi; Tobias Chirwa; Herbert Cubasch
Journal:  Breast Cancer Res Treat       Date:  2020-09-01       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.